Kailera Therapeutics, Inc.

Ce a raportat Kailera Therapeutics, Inc. la 12 august 2026

Din raportul 8-K al companiei.

Conferințe de rezultate

Pentru Kailera Therapeutics, Inc. nu este disponibilă nicio transcriere a unei conferințe de rezultate.

Ce a spus conducerea

“Our second quarter marked another period of strong execution across the Kailera portfolio. We advanced our global Phase 3 KaiNETIC program for ribupatide injection, completed enrollment in our U.S. Phase 2b high-dose ribupatide injection trial with data expected in mid-2027, and opened our ribupatide oral IND, with initiation of our global Phase 3 obesity program planned for the first half of 2027,”

Citat cuvânt cu cuvânt din comunicat și afișat doar atunci când raportarea îl atribuie unei persoane numite.

Cum a reacționat prețul

Comunicatele apar după închidere sau înainte de deschidere, deci mișcarea este cea a ședinței următoare.

Cu ce se ocupă Kailera Therapeutics, Inc.

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA.

Descrierea proprie a companiei, așa cum apare la finalul comunicatului.